The American Journal of Managed Care

FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed noninferiority ...
The American Journal of Managed Care

FDA Approves Use of Subcutaneous Pembrolizumab for NSCLC, Most Solid Tumors

FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...